WASHINGTON, Nov. 4, 2010 /PRNewswire-USNewswire/ -- In what is a watershed moment in the effort to save lives from the nation's number one cancer killer, groundbreaking news from the National Cancer Institute (NCI) today confirms what many in the public health community have long held out hope for - that low dose lung cancer screening will revolutionize the battle to detect tobacco-related lung cancers early enough to save countless lives.
The National Lung Cancer Screening Trial (NLST) has been halted because for high risk, heavy smokers, ages 55-74, low dose helical computed tomography (CT) scans have clearly demonstrated a statistically significant reduction in lung cancer mortalities.
Legacy first came out in support of the promise of this technology in 2004, before most in public health were willing to do so. Legacy has long funded the work of world-renowned and courageous radiologist, Dr. Claudia Henschke, a champion of CT scan technology, even when her work was considered controversial. Legacy is funding an ongoing analysis of the pressing question of whether CT scans for lung cancer will encourage smokers to quit or make them delay cessation even longer.
"We have been confident for many years that science would eventually find better ways to detect and treat lung cancers," said Cheryl G. Healton, DrPH, president and CEO of Legacy. "A growing body of evidence both in and outside the United States has been mounting for years that lung cancer screening saves lives. These findings suggest that CT screening for lung cancer should be incorporated into evidence-based practice and reimbursed in the same manner as mammography screening. In a